JPRN-jRCT1071230045已完成Unknown
The administration study of hematopoietic agents, antidiuretics, plasma substitutes and cortisol synthesis inhibitor in healthy adults
Ikushima Ippei0 个研究点目标入组 42 人开始时间: 2023年7月25日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 35age old（—）
- 性别
- All
入选标准
- •a. Age: 20 to 35 years (at the time when consent is given)
- •b. BMI at the time of prior examination :
- •Males 18.5 or more and less than 25.0, Female 17.6 more and less than 26.4
- •c. Individuals who the principal or subinvestigator believes to be acceptable for the study
排除标准
- •a. Those who have a history of allergic symptoms due to drugs;
- •b. Those who are suspected of having an infectious disease, including SARS CoV 2 infection;
- •c. Those who are undergoing any therapy now or will undergo any therapy during the study period;
- •d. Those who were or are alcoholic, drug addicted, or depressed;
- •e. Those who have a history of or are suspected of having one of the following diseases;
- •Study Drug 1 to Study Drug 5:
- •Cerebral infarction, myocardial infarction, thromboembolism such as pulmonary embolism, cardiovascular disease, stroke, central hypothyroidism, hypertension, malignant tumor, proliferative diabetic retinopathy, macular edema, exudative age related macular degeneration, retinal vein occlusion and liver dysfunction
- •Study Drug 6 to Study Drug 9:
- •myocardial infarction, pulmonary infarction, cerebral infarction, hypertension and hyperkalemia
- •Study Drug 10:
- •Hyponatremia, habitual or psychogenic polydipsia, fluid retention requiring treatment with diuretics, syndrome of inappropriate secretion of antidiuretic hormone, renal dysfunction, cardiovascular disease with hypertension, severe disease, Arteriosclerosis, coronary artery thrombosis, angina pectoris, heart failure and anterior pituitary insufficiency
- •Study Drug 11:
- •Congenital long QT syndrome, congestive heart failure, bradyarrhythmia, hypokalemia, hypomagnesemia and other electrolyte abnormalities, hypertension, liver dysfunction, adrenal cortical dysfunction
- •Study Drug 12:
- •Pulmonary edema, congestive heart failure, renal dysfunction such as renal failure with oliguria or anuria, intracranial hemorrhage, hypernatremia, hyperchloremia, bleeding diathesis
- •f. Those who have a history of using ethical or over the counter drugs within five weeks ahead of administrating the study drug;
- •g. Those who have a history of consuming supplements, foods containing St. John's Wort, grapefruit, or its processed products within one week ahead of administrating the study drug
- •h. Those who have a history of treatment with other investigational or study drugs within 16 weeks before administration of the study drug or treatment with other investigational or study drugs containing approved ingredients within 12 weeks before administration of the study drug;
- •i. Those who have a history of having 200 mL or more of blood or 400 mL or more of blood sampled within 30 or 90 days before administrating the study drug, respectively, or a history of blood component transfusion within 14 days or whole blood transfusion within 90 days before administrating the study drug;
- •j. Those who weigh less than 50 kg for a male and less than 40 kg for a female at the time of preliminary
研究者
相似试验
招募中
Unknown
Effect of hematopoietic growth factors therapy on brain injuryDiseases of the circulatory systemKCT0008633Yonsei University Health System, Severance Hospital60
已完成
不适用
Clinical trial of haplo-identical hematopoietic stem cell transplantation for treatment of refractory malignancies in childrerefractory malignanciesJPRN-UMIN000013692Department of pediatrics, Kanazawa university10
招募中
2 期
Hematopoietic stem cell gene therapy study2024-515253-25-00Orchard Therapeutics (Europe) Limited20
已完成
1 期
A phase I/II clinical trial of hematopoietic stem cell gene therapy for Wiskott-Aldrich SyndromeWiskott-Aldrich syndromeJPRN-UMIN000030806ational Center for Child Heath and Development3
进行中（未招募）
1 期
Phase 1/2 clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome - Gene therapy for WASEUCTR2009-011152-22-FRGENETHO10